Find the right fit for you - faster
Get tailored insights about working at CellCarta in one quick step.
CellCarta Snapshot
Our name is CellCarta. Our promise is health.
Together, we’re united by the truths that lay hidden deep within our cells and joined in a cause as great as humanity itself: to harness our understanding of precision medicine, to chart a course that leads to safer, more effective solutions, ensuring a healthier future for us all.
OUR CORE PURPOSE
Propelling precision medicine to improve human health.
OUR VISION
To be the global partner of choice for precision medicine solutions.
OUR CORE VALUES
We trust and respect each other.
We are driven by a powerful combination of passion and perseverance.
We collaborate to deliver excellence.
Together, we’re united by the truths that lay hidden deep within our cells and joined in a cause as great as humanity itself: to harness our understanding of precision medicine, to chart a course that leads to safer, more effective solutions, ensuring a healthier future for us all.
OUR CORE PURPOSE
Propelling precision medicine to improve human health.
OUR VISION
To be the global partner of choice for precision medicine solutions.
OUR CORE VALUES
We trust and respect each other.
We are driven by a powerful combination of passion and perseverance.
We collaborate to deliver excellence.
As a global Contract Research Organization Laboratory (CRO) to the biopharmaceutical industry, CellCarta provides access to a broad offering of biomarker platforms and services. We partner with you to address the most complex scientific testing needs, delivering customized biomarker testing solutions to further the limitless potential of precision medicine.
CellCarta, which is under the private ownership of Arsenal Capital, is the union of scientific pioneers of the CRO industry supporting discovery, translational research, and clinical research. At the core of CellCarta is the 2019 fusion of Caprion Biosciences and HistoGeneX which brought together a unique combination of biomarker expertise focused on immune monitoring, histopathology, proteomics and genomics, including the capabilities of previously acquired Primity Bio and Serametrix.
Leveraging its presence on four continents and through the addition of Clinical Logistics Inc., Mosaic Laboratories and Biogazelle, which further expanded its specimen logistics services and biomarker franchise, CellCarta is uniquely positioned to provide complex and customized clinical biomarker solutions at the global level.
CellCarta has over 20 years of advanced biomarker expertise and bioanalytical testing solutions, consists of 11 facilities in five countries, and is made up of over 1000 employees globally.
CellCarta, which is under the private ownership of Arsenal Capital, is the union of scientific pioneers of the CRO industry supporting discovery, translational research, and clinical research. At the core of CellCarta is the 2019 fusion of Caprion Biosciences and HistoGeneX which brought together a unique combination of biomarker expertise focused on immune monitoring, histopathology, proteomics and genomics, including the capabilities of previously acquired Primity Bio and Serametrix.
Leveraging its presence on four continents and through the addition of Clinical Logistics Inc., Mosaic Laboratories and Biogazelle, which further expanded its specimen logistics services and biomarker franchise, CellCarta is uniquely positioned to provide complex and customized clinical biomarker solutions at the global level.
CellCarta has over 20 years of advanced biomarker expertise and bioanalytical testing solutions, consists of 11 facilities in five countries, and is made up of over 1000 employees globally.
